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MCnorm and MCopt have a value of GTV D50 and Dmean 
comparable to the RT plan and higher than the MCrecalc 
plan. At the same time, MCnorm plans could not always be 
accepted referring to OARs dose constraints respect and 
target dose conformity (see Fig.1). Results are reported in 
Table 1. 
 
 
Conclusion: Lower variation of GTV dose parameters 
compared with PTV, when both RT and MCrecalc treatment 
plans are evaluated, suggests that GTV should be used for 
dose normalization and reporting instead of PTV. According 
to van der Voort van Zyp et al. (2010, [2]), a different 
prescription dose could be adopted, depending on lesion size 
and location. Moreover, MCopt plans need to be 
implemented, adopting a different prescription dose based 
on GTV D50 and Dmean values [1], as MCnorm plans could not 
guarantee appropriate target coverage and OARs sparing. 
Further multivariate analysis is mandatory to determine if 
there are correlations between the variables (size and 
location of the lesions, type of tracking adopted) considered 
for plan comparisons. 
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Purpose or Objective: To develop a dysphagia optimised 
IMRT (Do-IMRT) technique comparing fixed-field IMRT with 
VMAT for treatment of head and neck cancer in the DARS 
clinical trial (CRUK/14/014), which is a phase III randomised 
multicentre study of Do-IMRT versus standard IMRT (S-IMRT). 
 
Material and Methods: Six oropharynx cases were outlined 
and planned according to the DARS trial QA guidelines. CTVs 
were outlined using a volumetric approach with a 10mm GTV-
CTV expansion. Pharyngeal constrictor muscles (PCM) were 
also delineated. The dose levels prescribed were 65 Gy to the 
primary site and involved nodes and 54 Gy to the elective 
volume in 30 fractions. Plans were produced according to 
both arms of the trial using both fixed-field IMRT and VMAT 
(RapidArc) with an Eclipse treatment planning system 
(version 11). In the experimental Do-IMRT arm, the aim was 
to achieve a mean dose of less than 50 Gy to the superior and 
middle PCMs, excluding the CTV receiving 65 Gy 
(PlanSMPCM), and less than 20 Gy to the similarly edited 
inferior PCM (PlanIPCM). These constraints were prioritised 
over coverage of the PTV receiving 54 Gy (PTV_5400) but not 
the PTV receiving 65 Gy (PTV_6500). In the S-IMRT arm no 
attempt was made to reduce PCM doses. Plans were assessed 
for their clinical acceptability and DVH statistics compared. 
 
Results: Using fixed-field IMRT for Do-IMRT, it was not 
possible to achieve clinically acceptable plans in terms of 
both PTV_5400 95% isodose coverage and homogeneity whilst 
achieving the PCM constraints. However, using VMAT for Do-
IMRT a PlanSMPCM mean dose of less than 50 Gy was 
achieved in all cases, reduced by 8 Gy on average compared 
to S-IMRT. PlanIPCM mean doses of less than 20 Gy were 
achieved in the majority of cases, reduced by 30 Gy on 
average compared to S-IMRT. Do-IMRT plans had decreased 
but acceptable dose homogeneity and 95% isodose coverage 
was maintained, only compromising in the region where PCMs 
and PTV_5400 overlap (as shown in the example in figure 1). 
Other OAR (spinal cord, brainstem and parotids) doses were 
increased for Do-IMRT but critical OAR constraints were still 
achieved in all cases. The results are summarised in table 1. 
 
 
 
Figure 1: Dose distribution (colour wash displays 95-107% of 
54 Gy) of transverse slice showing PTV_5400 (blue) coverage 
using S-IMRT (left) compared to Do-IMRT (right), where 
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coverage is compromised in the region of PlanSMPCM 
(yellow).  
Table 1: Comparison of VMAT S-IMRT and Do-IMRT plan dose-
volume statistics for PlanPTVs (edited 5mm from body 
surface and excluding PlanPTV_6500 from PlanPTV_5400), 
spinal cord, brainstem, contralateral (CL) and ipsilateral (IL) 
parotids, PlanSMPCM and PlanIPCM. 
 
 
 
Conclusion: Do-IMRT can be achieved using VMAT for the 
DARS trial. Fixed-field IMRT may also be used to reduce 
constrictor dose, however is unlikely to produce plans 
acceptable within the DARS trial QA guidelines. 
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Purpose or Objective: RT plan rejections are defects that 
cause suboptimal or erroneous treatments if undetected and 
should be a focus of improvement. Applying the DMAIIC 
(Define, Measure, Analyze, Improve, Implement, and Control) 
formalism to clinic workflow provides actionable parameters 
for feedback and process correction. In our clinic, a web-
based treatment planning board shows the real-time 
workflow and compiles causes of plan rejection, which can 
be categorized and quantified for subsequent process 
improvement efforts. 
 
Material and Methods: Data was collected from July 2014-
September 2015. 341 (of 673) entries associated with plan 
rejection were categorized as changes in one of the 
following: (1) tumor anatomy/patient setup; (2) 
dose/volume; (3) tumor/OAR constraints; (4) treatment 
planning modification generated during plan review; and (5) 
external (patient-, disease-, or hospital/equipment-
generated) causes. Each entry was initiated by the physician, 
physicist, or dosimetrist involved in planning. Analyzed time 
intervals included the following: (1) dosimetry contours; (2) 
MD contour approval; (3) dosimetry plan computed; (4) 
physics plan precheck; (5) MD plan approval; and (6) total 
time for planning from simulation/planning board entry until 
MD plan approval (TMD). The data was analyzed with Two-
way ANOVA, Student T-test, and Pearson correlation. 
 
Results: The mean TMD time was 85 hrs (+/- 45). With 
breakdown by interval, the mean dosimetry contour (16 hrs), 
MD contour approval (27 hrs), dosimetry planning (12 hrs), 
physics precheck (4 hrs), and MD approval (11 hrs) times were 
calculated. The planning modification category was a 
significant source of variation in planning time (p<0.0001). 
Treatment planning modifications presented the predominant 
(50%) source of planning delay, followed by constraint (26%), 
dose/volume (18%), external (4%), and tumor 
anatomy/patient setup changes (2%). Those with tumor 
anatomy/patient setup or dose/volume changes resulted in 
the longest TMD, dosimetry contour, dosimetry plan 
computing, and MD plan approval intervals. 27% of plan 
modifications were initiated by physicians, 70% by physicists, 
and 3% by dosimetrists. Entries initiated by physicians on the 
planning board were associated with shorter TMD times than 
when physicists initiated plan rejection (p=0.016). 
 
Conclusion: We report a novel process for quantification of 
clinical RT plan rejections. In this analysis, tumor 
anatomy/patient setup or dose/volume changes resulted in 
the longest treatment TMD times. Physician-initiated plan 
modification entries were associated with shorter TMD times, 
which may denote early, proactive involvement—an optimal 
approach with complicated or aggressive disease. Though 
planning delays may depend on department infrastructure 
and patient population, our method provides a 
comprehensive census to optimize planning throughput and 
can be applied as a part of broader process improvement. 
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Purpose or Objective: Craniospinal irradiation is performed 
rarely in a palliative intention due to concerns of acute 
toxicities (mostly dysphaghia and bone marrow supression). 
Therefore the purpose of this study was to evaluate the 
dosimetric parameters responsible for the acute toxicity in 
patients with leptomeningeal metastasis of a solid cancer 
treated with craniospinal irradiation (CSI) by helical 
tomotherapy (HT), 3D conformal radiotherapy (3D-CRT) and 
Protons. 
 
Material and Methods: Data of five adult patients previously 
treated with HT CSI were evaluated. For each patient the 
initial tomotherapy plan (inHT) was compared to a 3D 
conformal plan (3D-CRT), a scanning proton beam plan (p-
CSI) as well as to a specifically optimized bone marrow (BM) 
sparing tomotherapy plan (BM-HT). The BM-HT was also 
optimized to reduce the acute dysphagia. The prescribed 
dose was 36 Gy. All active bone marrow compartments were 
delineated separately according to Campbell et al. To 
analyse the impact of different bone marrow compartments 
weighted bone marrow exposure (WBME) was used. 
WBME Dmean =Σ(proportion (%) of functional bone marrow 
according to anatomical site x Dmean to anatomical site)  
WBME V20=Σ(proportion (%) of functional bone marrow 
according to anatomical site x V20 to anatomical site)  
This calculation was also performed for V30. 
Further, the following organ at risks (OARs) were delineated: 
left and right submandibular glands, the parotid glands, the 
eyes, the cochlea, the oral cavity, the pharynx, the thyroid 
gland, the esophagus, the heart, both lungs, both kidneys, 
the liver, the bowel, and the pancreas. For all of these 
structures the Dmean in all four treatment plans were 
analyzed. 
Descriptive statistics were used to analyze the results. 
 
Results: p-CSI results in the best sparing of the organs at risk 
(OARs) including the active bone marrow compartments. BM-
HT achieved better results as inHT and 3D-CRT regarding 
bone marrow sparing (see Figure 1.). Dose to the crucial OARs 
responsible for dysphagia was also reduced with BM-HT. The 
trade off for this was an slightly increased lung and kidney 
dose. 
 
